Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

66 results about "Fluorescent polarization" patented technology

Multiplex binding and activity assays

Compositions, including antibodies, polypeptides, and organic molecules, kits, apparatuses, and methods for probing molecular interactions using fluorescence polarization (FP) and / or time-resolved resonance energy transfer (TR-RET) are provided.
Owner:LIFE TECH CORP

Method and system for measuring membrane potential based on fluorescence polarization

InactiveUS20070254276A1Simple and accurate and inexpensive to performMicrobiological testing/measurementBiological testingFluorescenceFluorescent polarization
A method of determining a membrane potential is disclosed. The method comprises (a) determining a difference in fluorescence polarization of a charged fluorescent probe being distributed across the membrane; and (b) determining a potential of the membrane, wherein the potential is proportional to the difference in the fluorescent polarization.
Owner:SENG ENTERPRISES

Assays for detection of bioactive compounds that interact with heat shock protein 90

InactiveUS20070178537A1Low costHigh ATPase activityCompound screeningHybrid immunoglobulinsCell based assaysHsp90 binding
A method for evaluation of molecules to identify those that can act as therapeutic inhibitors of Hsp90 makes use of a fluorescence polarization (FP) assay and a cell based assay, either individually or in combination. The FP assay uses a fluorescently-labeled Hsp90 binding agent and measure the degree of fluorescence polarization relative to the standard. A decrease in the degree of polarization indicates that fluorescently-labeled Hsp90 binding agent has been wholly or partially displaced by a candidate molecule, and identifies the molecule as having activity as an inhibitor of Hsp90. The cell based assay tests for decrease is an Hsp90-dependent activity of normal or tumor cells.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Stable polypeptide targeting SARS-CoV-2 spike protein and application of stable polypeptide

The invention provides a stable polypeptide targeting SARS-CoV-2 spike protein. A template amino acid sequence structure of the stable polypeptide is X-(Linker)-CONH-IEEQAKTFLDKFNHEAEDLFYQS-CONH2. Theinvention also provides application of the polypeptide in preparation of a medicine for treating SARS-CoV-2. The invention also provides application of the polypeptide in preparation of a medicine for preventing the SARS-CoV-2 from entering human cells. The polypeptide molecule is combined with the spike protein to block virus from entering the human body by being combined with human ACE2. Experiments of fluorescence polarization detection and the like prove that the polypeptide disclosed by the invention can be well combined with an RBD of the spike protein and has an effect of blocking a virus infection process.
Owner:PEKING UNIV SHENZHEN GRADUATE SCHOOL +1

Systems and methods for allergen detection

The present invention provides systems, devices, signaling polynucleotides (SPNs), detection agents and methods for detecting the presence and / or absence of one or more allergens in a sample particularly a food sample. The detection system includes a separate sampler, at least one disposable detection vessel for receiving and processing a test sample and a detection device for measuring a fluorescent signal. SPNs derived from aptamer that bind allergens are provided as detection agents. SPNs have a single open structure, and are labeled with a fluorophore. Changes in fluorescence polarization of SPNs upon the binding of allergens are measured to calculate the allergen content in a sample.
Owner:DOTS TECH CORP

Development of a novel assay for mgmt (methyl guanine methyl transferase)

The present invention provides improved methods for assessing the level of MGMT activity in a variety of biological preparations. MGMT, a DNA repair enzyme, can reduce the chemotherapeutic efficacy of alkylating agents by repairing the damage that alkylating agents do to tumor cell DNA. The methods of the present invention can be used, inter alia, to measure MGMT levels and to thereby predict the clinical response to alkylating agents. The present invention includes three preferred assays for assessment of MGMT activity: (1) the immunoassay technique, (2) the labeled O6—BG technique, and (3) the fluorescence polarization technique. Kits useful for the performance of such assays are also provided.
Owner:SCHERING CORP

Methods for identifying nucleotides at defined positions in target nucleic acids using fluorescence polarization

The invention provides a method for identifying a nucleotide at a defined position in a target nucleic acid using restriction endonucleases and fluorescence polarization. The invention further provides compounds, compositions, and kits related to the method.
Owner:KECK GRADUATE INST OF APPLIED LIFE SCI

Fluorescence polarization screening method

A method for screening for a nucleotide sequence encoding for a biological compound comprising measuring the fluorescence polarization of a fluorescent substance reacting with the biological compound expressed by an expression system comprising the nucleotide sequence.
Owner:NOVO NORDISK AS

Topoisomerase Binding Probe and Method of Use

An aminocoumarin conjugated to a fluorescent label through a secondary amine, is operative as a fluorescent polarization probe of the DNA gyrase B or topoisomerase IV E subunit. The probe is used for detecting topoisomerase inhibitor binding by fluorescence polarization, particularly in a high-through put topoisomerase inhibitor assay.
Owner:SRI INTERNATIONAL

Assay methods and systems

Methods, systems, kits for carrying out a wide variety of different assays that comprise providing a first reagent mixture which comprises a first reagent having a fluorescent label. A second reagent is introduced into the first reagent mixture to produce a second reagent mixture, where the second reagent reacts with the first reagent to produce a fluorescently labeled product having a substantially different charge than the first reagent. A polyion is introduced into at least one of the first and second reagent mixtures, and the fluorescent polarization in the second reagent mixture relative to the first reagent mixture is determined, this fluorescent polarization being indicative of the rate or extent of the reaction.
Owner:CAPLIPER LIFE SCI INC

Method for determining the glucose concentration by fluorescence polarization

The invention generally relates to a method for in vivo glucose monitoring in which the glucose concentration is measured by means of fluorescence polarization by detecting the change in viscosity, caused by changes in the glucose concentration.
Owner:ROCHE DIABETES CARE INC

Fluorescent polarization method, kit used therefor and biosensor

A fluorescence polarization assay is a method for measuring a subject substance, which includes the steps of: (a) preparing a first solid support body on which a binding substance capable of specifically binding to the subject substance is immobilized and a fluorescent labeled substance which is capable of specifically binding to the subject substance and is labeled with a fluorescent dye; (b) bringing the fluorescent labeled substance and the binding substance into contact with the subject substance; and (c) measuring the polarization degree of fluorescent light from the fluorescent labeled substance.
Owner:PANASONIC CORP

Method for determining activity of O-linked N-acetylglucosamine transferase and application of method

The invention relates to the technical field of biological analysis and detection, in particular to a method for determining the activity of O-linked N-acetylglucosamine transferase and application ofthe method. The method comprises the following steps: firstly, modifying a glycosyl receptor of OGT by utilizing a fluorescent group, transferring azide-modified glycosyl to polypeptide through an enzyme reaction catalyzed by OGT, and then connecting the glycosyl receptor to macromolecular bovine serum albumin modified by dibenzocyclooctyne through a click reaction. The property that bovine serumalbumin is a macromolecule is utilized, and the bovine serum albumin is used as an 'FP tag 'capable of causing polarization signal enhancement, so that the enzyme activity of OGT is visually displayed. According to the invention, the problem of low catalytic activity of OGT on a complex modified substrate is solved, meanwhile, the correlation between the enzyme activity and the fluorescence polarization signal size is realized, and the method can be used for determining the enzyme activity of OGT, and can also be used for high-throughput screening of an OGT inhibitor and determination of theinhibitory activity of the OGT inhibitor.
Owner:SUN YAT SEN UNIV

Chemically modified basic group-containing single-stranded DNA aptamer capable of specifically recognizing anthrax protective antigen PA83 and application thereof

The invention discloses a chemically modified base-containing single-stranded DNA aptamer capable of specifically recognizing anthrax protective antigen PA83 and application thereof. According to thechemically modified base-containing single-stranded DNA aptamer, the anthrax protective antigen (PA83) is taken as a target, a nucleic acid library containing chemically modified nucleotides is utilized, a high-affinity aptamer AP5 is screened out by a paramagnetic particle method SELEX, and the aptamer can specifically recognize PA83 protein in the environment of various interference proteins; the aptamer can be applied to an aptamer biosensor based on a surface plasmon resonance technology and a fluorescence polarization technology and used for detecting PA83 protein so as to detect bacillusanthracis, and the aptamer has the potential of being applied to construction of a novel bacillus anthracis protective antigen detection technology.
Owner:中国人民解放军疾病预防控制中心

Compositions and methods for inhibiting resolvases

The invention provides a fluorescence polarization (FP)-based assay to identify inhibitors of resolvase's DNA cleavage activity. The invention also provides resolvase inhibitors identified by the assay, as well as derivatives and analogs thereof. In certain embodiments, the compounds of the invention are useful to treat a poxvirus infection in an infected subject.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Tripolycyanamide single-reagent polarization fluoroimmunoassay

InactiveCN102721803AEasy to operateEasy to transportMaterial analysisPolarization FluoroimmunoassayImmune complex
The invention discloses a tripolycyanamide single-reagent polarization fluoroimmunoassay. A stable and sensitive single-reagent immunocomplex is prepared by the method, and can be stably preserved for at least more than one month at the temperature below 4 DEG C. For the tripolycyanamide polarization fluoroimmunoassay established on this basis, washing and separation are not required in the reaction process, and the detection result can be obtained just through a short-time one-step reaction between a specimen to be detected and the single-reagent immunocomplex, wherein the detection limit is 3.2 ng / mL, and the detection range is 12.2-1012.4 ng / mL. Thus, the tripolycyanamide single-reagent polarization fluoroimmunoassay is a fast and convenient high-flux tripolycyanamide detection method, is very suitable for the practical detection application of tripolycyanamide, and lays a foundation for developing an on-site detection kit in future.
Owner:SOUTH CHINA AGRI UNIV

A method of determining the abundance of a target molecule in a sample

A method for determining the abundance of a target molecule in a liquid sample comprising the steps of incubating in a reaction chamber the liquid sample with a target molecule-binding probe comprising a single domain antibody conjugated to a fluorescent probe to provide a reaction mixture, assaying the reaction mixture in the reaction chamber for fluorescence polarisation to detect a change in polarisation between excitation and emission light, and correlating the change in polarisation with the abundance of the target molecule in the sample.
Owner:VALITACELL

Method and screening model for screening small-molecule inhibitor of main protease of new coronavirus

PendingCN113699212AHigh mP valueLow mP valueHydrolasesMicrobiological testing/measurementFluoProbesHydrolysis
The invention relates to a method and a screening model for screening a small-molecule inhibitor of main protease (Mpro) of a new coronavirus. The method and the screening model are based on the basis of a fluorescence polarization principle, a fluorescent probe FITC-Substrate-Biotin is used as a hydrolysis substrate of the new coronavirus Mpro, avidin is used for terminating the hydrolysis reaction of the new coronavirus Mpro, and a multifunctional microplate reader is used for detecting the millipolarization units (mP) of an experimental system. The active compound shows a high mP value in the screening model, and the inactive compound shows a low mP value.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Fluorescent polarization based homogeneous phase detection method of single nucleotide polymorphism of codon118 of ERCC1 (excision repair cross-complementing 1) gene

The invention relates to a fluorescent polarization based homogeneous phase detection method of a single nucleotide polymorphism of a codon118 of an ERCC1 (excision repair cross-complementing 1) gene. The homogeneous phase detection method solves the problems of high cost, complicated operating steps, proneness to causing contamination and influence on detection result accuracy in the prior art, and is simple in steps, easy to operate, not prone to causing contamination as operation can be completed once in a closed tube, and low in cost as any special reagent and fluorescence quenching or micro-groove binding agent are not needed. Application of a specific probe with single end marked to detection of the single nucleotide polymorphism of the codon118 of the ERCC1 gene results in changes of fluorescent polarization values and enables detection results to be more objective and accurate. Result analysis is simple as only numeric comparison is needed in result judgment, and the homogeneous phase detection method can easily realize standardization and automation, is wide in application range and can be used for detecting clinical blood or tissue specimens.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products